Importantly, the CANTOS study showed that canakinumab, an interleukin-1 (IL-1) inhibitor, significantly decreased hsCRP levels and the incidence of cardiovascular events in individuals with a history of myocardial infarction and elevated hsCRP (24). Here, IL1B is linked to myocardial infarction.